Genmab A/S ADS (GMAB) is higher today after a bullish analyst action lifted sentiment around the company’s late-stage pipeline. Goldman Sachs upgraded Genmab to Buy from Neutral on April 22, 2026, pointing to increased confidence in multiple pipeline programs and the potential to de-risk more than $5 billion in peak sales opportunity through the remainder of 2026. (au.finance.yahoo.com)

The upgrade lands as investors weigh Genmab’s transition toward a broader, more diversified growth story beyond its flagship royalty stream. Recent company updates have kept attention on underlying commercial momentum from DARZALEX (daratumumab), with worldwide net trade sales reported at about $3.964 billion for the first quarter of 2026, reinforcing the durability of the core earnings engine that funds pipeline investment. (ir.genmab.com)

Near-term focus is likely to remain on additional clinical updates and clarity on how quickly pipeline programs can translate into revenue diversification. Investors are also monitoring capital returns, as Genmab has continued activity tied to its share buy-back program and related transaction updates. (tipranks.com)